Systemic barriers beyond just the price of drugs can impact health care costs, emphasizing the need for comprehensive ...

Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

In an executive order last week, President Donald Trump effectively instituted price controls on prescription drugs—not just those purchased by the government through Medicare and Medicaid ...

The Trump administration shared on Tuesday the outlines of how it plans to push pharmaceutical companies to lower their US drug prices to bring them more in line with other nations, kicking off ...

More recently, President Joe Biden tried, and failed, twice to get a law through Congress allowing the government to negotiate the price of drugs to bring them in line with prices in other rich ...

Indian pharma companies that provide research services could take a hit from US President Donald Trump’s executive order on cutting prices of prescription drugs, analysts told Mint. The order ...

Drug manufacturers submitted proposals last year to switch from discount models to rebate models — providers would to pay full price for some medications, then submit claims data for ...

After Donald Trump signed an executive order slashing drug prices last week, experts have highlighted how pharmacy benefit managers (PBMs) could be hit the hardest despite pharmaceutical companies ...

Donald Trump's recent executive orders slashing drug prices and demanding transparency in pharmacy benefit manager fees are putting pressure on drug industry middlemen, according to Benzinga.

On Monday, the president issued an Executive Order (EO) he says will decrease the cost of drugs in America and lead to increased transparency about how pharmaceutical companies set prices.

This article originally appeared on PolitiFact. President Donald Trump expressed high hopes for an executive order to reduce drug prices. On May 11, the day before he held a White House event to ...

FRANKFURT – Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy ... a steep decline in the company's share price. Lars Fruergaard Jorgensen's departure ...